This article was originally published in The Gray Sheet
Executive SummaryDeveloper of the STOP (selective tubal occlusion procedure) non-surgical permanent contraception device for women announces completion of a private placement of 1.9 mil. shares at $7.26 each. Net proceeds of $14 mil. will allow Conceptus to "continue to ramp up our pivotal trial of the STOP device, accelerate marketing in Australia and other international markets, and...invest in our manufacturing and distribution operations," the company says. PaineWebber served as placement agent
You may also be interested in...
Now that the UK has left the EU, the UK’s medicines regulator says it will use the rest of this year to work out how best to ensure continuity of drug regulation after the Brexit transition period ends on 31 December.
The Coronavirus outbreak makes its first dent into pharma's 2020 prospects as AstraZeneca admits possible impact, while could AbbVie's aesthetic plans raise the prospect of another GSK-style spin off?
French off-patent industry association Gemme has declared a “state of emergency” for French generics as it revealed industry data for 2019 pointing to weak growth. Meanwhile, Gemme says, the country’s biosimilars market is “dynamic” and growing quickly but is still under-performing.